Illumina next-generation sequencing (NGS) and microarray technologies represent the gold standard in quality worldwide—and account for ~90% of the world’s sequencing data.* Innovative, intuitive, and completely integrated, our sample-to-data solutions empower your lab to keep ahead of the curve in the rapidly evolving genomics revolution. So you’ll be better able to perform the world-class research you strive for—with the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Our comprehensive product offerings support multiple cancer research applications, including studies of DNA, RNA, epigenetics, and more. Our range of sequencers can be scaled to meet your needs—from powerful, yet personal, benchtop models to versatile, high-throughput systems. With intuitive data analysis and management capabilities and unsurpassed customer support, we can deliver the answers you seek—quickly, accurately, and cost-effectively.
Explore genomics-based approaches to investigating cancer using NGS and microarrays.
NGS technology has accelerated the discovery of variants associated with cancer. Some of these research discoveries became the basis for companion diagnostics and laboratory developed tests (LDT) now in use in molecular diagnostic laboratories worldwide. We spoke with key opinion leaders about the ongoing challenges and potential of NGS in oncology testing.
Read InterviewStudies from Japan and Belgium seek to advance precision medicine in oncology
Read ArticleDeveloping and automating best-practice workflows that make analyzing, processing, and disseminating genomic data accessible to researchers and clinicians.
Read InterviewPositioning Australia at the forefront of healthcare innovation
Read ArticleLearn the numerous ways that genomic technologies can be applied to tumor biology.
An overview of recent cancer genomics research publications featuring Illumina technology.
Munich Leukemia Laboratory is using NGS to gain a better understanding of leukemia and lymphoma subtypes and discover new therapeutic pathways.
Explore a variety of webinars on topics ranging from cancer research to NGS data analysis, microbiome studies, and more.
A researcher from Massachusetts General Hospital compares sequencing results from FFPE and fresh-frozen tumor samples.
*Data on file based on a 2013 study.